ONC vs. SBTX, OBD, DEST, OPTI, HEMO, OBI, NSCI, C4XD, SNG, and SAR
Should you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include SkinBioTherapeutics (SBTX), Oxford BioDynamics (OBD), Destiny Pharma (DEST), OptiBiotix Health (OPTI), Hemogenyx Pharmaceuticals (HEMO), Ondine Biomedical (OBI), NetScientific (NSCI), C4X Discovery (C4XD), Synairgen (SNG), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics (LON:SBTX) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
SkinBioTherapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
In the previous week, Oncimmune's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.
SkinBioTherapeutics has higher earnings, but lower revenue than Oncimmune. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
Oncimmune has a net margin of 356.25% compared to Oncimmune's net margin of 0.00%. Oncimmune's return on equity of -118.63% beat SkinBioTherapeutics' return on equity.
12.0% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 35.5% of Oncimmune shares are held by institutional investors. 28.1% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 28.8% of Oncimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Oncimmune received 21 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
Summary
Oncimmune beats SkinBioTherapeutics on 7 of the 13 factors compared between the two stocks.
Get Oncimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncimmune Competitors List
Related Companies and Tools
